Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates

Bernard Moss; Miles W. Carroll; Linda S. Wyatt; Jack R. Bennink; Vanessa M. Hirsch; Simoy Goldstein; William R. Elkins; Thomas R. Fuerst; Jeffrey D. Lifson; M. Piatak; Nicholas P. Restifo; Willem Overwijk; Ronald Chamberlain; Steven A. Rosenberg; Gerd Sutter

doi:10.1007/978-1-4899-1382-1_2

Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates

Bernard Moss, Miles W. Carroll, Linda S. Wyatt, Jack R. Bennink, Vanessa M. Hirsch, Simoy Goldstein, William R. Elkins, Thomas R. Fuerst, Jeffrey D. Lifson, M. Piatak, Nicholas P. Restifo, Willem Overwijk, Ronald Chamberlain, Steven A. Rosenberg, Gerd Sutter

Research output: Contribution to journal › Article › peer-review

113 Scopus citations

Abstract

Three model systems were used to demonstrate the immunogenicity of highly attenuated and replication-defective recombinant MVA. (1) Intramuscular inoculation of MVA-IN-F(ha/np) induced humoral and cell-mediated immune responses in mice and protectively immunized them against a lethal respiratory challenge with influenza virus. Intranasal vaccination was also protective, although higher doses were needed. (2) In rhesus macaques, an immunization scheme involving intramuscular injections of MVA- SIV(env/gag/pol) greatly reduced the severity of disease caused by an SIV challenge. (3) In a murine cancer model, immunization with MVA-βgal prevented the establishment of tumor metastases and even prolonged life in animals with established tumors. These results, together with previous data on the safety of MVA in humans, suggest the potential usefulness of recombinant MVA for prophylactic vaccination and therapeutic treatment of infectious diseases and cancer.

Original language	English (US)
Pages (from-to)	7-13
Number of pages	7
Journal	Advances in experimental medicine and biology
Volume	397
DOIs	https://doi.org/10.1007/978-1-4899-1382-1_2
State	Published - 1996
Externally published	Yes

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1007/978-1-4899-1382-1_2

Cite this

Moss, B., Carroll, M. W., Wyatt, L. S., Bennink, J. R., Hirsch, V. M., Goldstein, S., Elkins, W. R., Fuerst, T. R., Lifson, J. D., Piatak, M., Restifo, N. P., Overwijk, W., Chamberlain, R., Rosenberg, S. A., & Sutter, G. (1996). Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Advances in experimental medicine and biology, 397, 7-13. https://doi.org/10.1007/978-1-4899-1382-1_2

Moss, B, Carroll, MW, Wyatt, LS, Bennink, JR, Hirsch, VM, Goldstein, S, Elkins, WR, Fuerst, TR, Lifson, JD, Piatak, M, Restifo, NP, Overwijk, W, Chamberlain, R, Rosenberg, SA & Sutter, G 1996, 'Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates', Advances in experimental medicine and biology, vol. 397, pp. 7-13. https://doi.org/10.1007/978-1-4899-1382-1_2

@article{7fa14d078e114fe2a6e325ababbbd593,

title = "Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates",

abstract = "Three model systems were used to demonstrate the immunogenicity of highly attenuated and replication-defective recombinant MVA. (1) Intramuscular inoculation of MVA-IN-F(ha/np) induced humoral and cell-mediated immune responses in mice and protectively immunized them against a lethal respiratory challenge with influenza virus. Intranasal vaccination was also protective, although higher doses were needed. (2) In rhesus macaques, an immunization scheme involving intramuscular injections of MVA- SIV(env/gag/pol) greatly reduced the severity of disease caused by an SIV challenge. (3) In a murine cancer model, immunization with MVA-βgal prevented the establishment of tumor metastases and even prolonged life in animals with established tumors. These results, together with previous data on the safety of MVA in humans, suggest the potential usefulness of recombinant MVA for prophylactic vaccination and therapeutic treatment of infectious diseases and cancer.",

author = "Bernard Moss and Carroll, {Miles W.} and Wyatt, {Linda S.} and Bennink, {Jack R.} and Hirsch, {Vanessa M.} and Simoy Goldstein and Elkins, {William R.} and Fuerst, {Thomas R.} and Lifson, {Jeffrey D.} and M. Piatak and Restifo, {Nicholas P.} and Willem Overwijk and Ronald Chamberlain and Rosenberg, {Steven A.} and Gerd Sutter",

year = "1996",

doi = "10.1007/978-1-4899-1382-1_2",

language = "English (US)",

volume = "397",

pages = "7--13",

journal = "Advances in Experimental Medicine and Biology",

issn = "0065-2598",

publisher = "Springer New York",

}

TY - JOUR

T1 - Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates

AU - Moss, Bernard

AU - Carroll, Miles W.

AU - Wyatt, Linda S.

AU - Bennink, Jack R.

AU - Hirsch, Vanessa M.

AU - Goldstein, Simoy

AU - Elkins, William R.

AU - Fuerst, Thomas R.

AU - Lifson, Jeffrey D.

AU - Piatak, M.

AU - Restifo, Nicholas P.

AU - Overwijk, Willem

AU - Chamberlain, Ronald

AU - Rosenberg, Steven A.

AU - Sutter, Gerd

PY - 1996

Y1 - 1996

N2 - Three model systems were used to demonstrate the immunogenicity of highly attenuated and replication-defective recombinant MVA. (1) Intramuscular inoculation of MVA-IN-F(ha/np) induced humoral and cell-mediated immune responses in mice and protectively immunized them against a lethal respiratory challenge with influenza virus. Intranasal vaccination was also protective, although higher doses were needed. (2) In rhesus macaques, an immunization scheme involving intramuscular injections of MVA- SIV(env/gag/pol) greatly reduced the severity of disease caused by an SIV challenge. (3) In a murine cancer model, immunization with MVA-βgal prevented the establishment of tumor metastases and even prolonged life in animals with established tumors. These results, together with previous data on the safety of MVA in humans, suggest the potential usefulness of recombinant MVA for prophylactic vaccination and therapeutic treatment of infectious diseases and cancer.

AB - Three model systems were used to demonstrate the immunogenicity of highly attenuated and replication-defective recombinant MVA. (1) Intramuscular inoculation of MVA-IN-F(ha/np) induced humoral and cell-mediated immune responses in mice and protectively immunized them against a lethal respiratory challenge with influenza virus. Intranasal vaccination was also protective, although higher doses were needed. (2) In rhesus macaques, an immunization scheme involving intramuscular injections of MVA- SIV(env/gag/pol) greatly reduced the severity of disease caused by an SIV challenge. (3) In a murine cancer model, immunization with MVA-βgal prevented the establishment of tumor metastases and even prolonged life in animals with established tumors. These results, together with previous data on the safety of MVA in humans, suggest the potential usefulness of recombinant MVA for prophylactic vaccination and therapeutic treatment of infectious diseases and cancer.

UR - http://www.scopus.com/inward/record.url?scp=9044232149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9044232149&partnerID=8YFLogxK

U2 - 10.1007/978-1-4899-1382-1_2

DO - 10.1007/978-1-4899-1382-1_2

M3 - Article

C2 - 8718576

AN - SCOPUS:9044232149

SN - 0065-2598

VL - 397

SP - 7

EP - 13

JO - Advances in Experimental Medicine and Biology

JF - Advances in Experimental Medicine and Biology

ER -

Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this